Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRSNASDAQ:ENTANASDAQ:KPTINASDAQ:MOLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.42+1.4%$1.32$1.05▼$5.17$151.59M0.411.19 million shs738,101 shsENTAEnanta Pharmaceuticals$7.23+2.6%$5.97$4.09▼$17.24$150.71M0.76284,786 shs98,747 shsKPTIKaryopharm Therapeutics$4.44+1.8%$5.10$3.51▼$17.40$37.71M0.2381,762 shs33,949 shsMOLNMolecular Partners$3.75-0.3%$3.90$3.36▼$12.70$151.81M1.1117,353 shs449 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics+1.43%-9.55%+9.23%-9.55%+25.66%ENTAEnanta Pharmaceuticals+2.55%-9.06%+21.31%+12.27%-38.88%KPTIKaryopharm Therapeutics+1.83%+1.14%-13.45%-27.69%-68.17%MOLNMolecular Partners-0.82%+2.99%-4.68%-8.76%-52.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics2.6713 of 5 stars3.61.00.00.02.91.71.3ENTAEnanta Pharmaceuticals3.7131 of 5 stars3.41.00.04.71.92.50.0KPTIKaryopharm Therapeutics3.7581 of 5 stars3.51.00.04.60.62.50.6MOLNMolecular Partners3.2165 of 5 stars3.85.00.00.03.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.11Buy$9.71584.10% UpsideENTAEnanta Pharmaceuticals 2.80Moderate Buy$18.00148.96% UpsideKPTIKaryopharm Therapeutics 3.00Buy$43.20872.97% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00220.00% UpsideCurrent Analyst Ratings BreakdownLatest KPTI, ACRS, ENTA, and MOLN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.005/28/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.005/14/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $16.005/13/2025KPTIKaryopharm TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$34.00 ➝ $33.005/13/2025KPTIKaryopharm TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.005/13/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$54.00 ➝ $42.005/9/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$18.72M8.21N/AN/A$1.44 per share0.99ENTAEnanta Pharmaceuticals$67.64M2.29N/AN/A$6.08 per share1.19KPTIKaryopharm Therapeutics$145.24M0.26N/AN/A($22.10) per share-0.20MOLNMolecular Partners$5.65M26.80N/AN/A$3.99 per share0.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$132.07M-$1.39N/AN/AN/A-732.42%-30.73%-22.74%8/6/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.54N/AN/AN/A-149.57%-79.83%-26.65%8/4/2025 (Estimated)KPTIKaryopharm Therapeutics-$76.42M-$13.26N/AN/AN/A-43.99%N/A-35.95%8/5/2025 (Estimated)MOLNMolecular Partners-$61.39M-$1.92N/AN/AN/A-1,043.01%-42.20%-38.12%8/25/2025 (Estimated)Latest KPTI, ACRS, ENTA, and MOLN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MOLNMolecular Partners-$0.3855-$0.50-$0.1145-$0.50N/AN/A5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million5/12/2025Q1 2025KPTIKaryopharm Therapeutics-$4.21-$2.77+$1.44-$2.77$35.12 million$30.02 million5/6/2025Q1 2025ACRSAclaris Therapeutics-$0.19-$0.12+$0.07-$0.12$3.55 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A5.065.06ENTAEnanta PharmaceuticalsN/A5.295.29KPTIKaryopharm TherapeuticsN/A1.331.28MOLNMolecular PartnersN/A15.2815.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%ENTAEnanta Pharmaceuticals94.99%KPTIKaryopharm Therapeutics66.44%MOLNMolecular Partners26.55%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics6.40%ENTAEnanta Pharmaceuticals13.89%KPTIKaryopharm Therapeutics2.98%MOLNMolecular Partners5.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.28 million101.35 millionOptionableENTAEnanta Pharmaceuticals16021.38 million18.41 millionOptionableKPTIKaryopharm Therapeutics3808.64 million8.38 millionOptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionableKPTI, ACRS, ENTA, and MOLN HeadlinesRecent News About These CompaniesMolecular Partners Reports Positive Phase 1/2a Data for MP0533 in Relapsed/Refractory AML at EHA CongressJune 12, 2025 | nasdaq.comMolecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025June 11, 2025 | uk.finance.yahoo.comMolecular Partners to cut jobs, cash reach now anticipated to extend into 2028June 10, 2025 | msn.comMolecular Partners (NASDAQ:MOLN) Shares Up 2.2% - What's Next?June 10, 2025 | americanbankingnews.comMolecular Partners (NASDAQ:MOLN) Shares Up 2.2% - Time to Buy?June 10, 2025 | marketbeat.comMolecular Partners Announces Planned Operational Efficiencies and Extension of Cash RunwayJune 10, 2025 | globenewswire.comBrokers Offer Predictions for MOLN Q2 EarningsMay 20, 2025 | marketbeat.comSuvretta Capital Management LLC Has $10.55 Million Stake in Molecular Partners AG (NASDAQ:MOLN)May 19, 2025 | marketbeat.comMolecular Partners to Present at Upcoming Investor ConferencesMay 19, 2025 | globenewswire.comMolecular Partners Reports Financial Results and Highlights from Q1 2025May 16, 2025 | finance.yahoo.comMolecular Partners presents new data on Radio-DARPin, Switch-DARPin programsApril 26, 2025 | markets.businessinsider.comMolecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025April 25, 2025 | globenewswire.comWhy Molecular Partners AG’s (MOLN) Stock Is Up 5.04%April 17, 2025 | aaii.comMolecular Partners Announces all Board Proposals Approved at Annual General MeetingApril 16, 2025 | globenewswire.comDendi and Molecular Lab Partners Announce Strategic Partnership to Empower Labs NationwideApril 15, 2025 | tmcnet.comHedge funds owners may take dramatic actions as Molecular Partners AG's (VTX:MOLN) recent 15% drop adds to one-year lossesApril 6, 2025 | finance.yahoo.comHere's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom FisherApril 3, 2025 | zacks.comWhy Molecular Partners AG’s (MOLN) Stock Is Up 9.28%March 27, 2025 | aaii.comMolecular Partners to hold three poster presentations at AACR 2025March 25, 2025 | globenewswire.comMolecular Partners Publishes Invitation to Annual General Meeting 2025March 25, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Molecular Partners (MOLN), United Therapeutics (UTHR) and Universal Health (UHS)March 17, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesA Large Oil Supply Draw Could Mean Upside in These 3 Energy NamesBy Gabriel Osorio-Mazilli | June 6, 2025View A Large Oil Supply Draw Could Mean Upside in These 3 Energy NamesASML’s AI Edge: How Its EUV Tech Is Creating a New MonopolyBy Jeffrey Neal Johnson | June 10, 2025View ASML’s AI Edge: How Its EUV Tech Is Creating a New MonopolyWhy Analysts Are Bullish on Celsius Stock After 30% DropBy Gabriel Osorio-Mazilli | June 16, 2025View Why Analysts Are Bullish on Celsius Stock After 30% DropIgnore the Noise—Samsara Stock Is Still a Strong BuyBy Sam Quirke | June 12, 2025View Ignore the Noise—Samsara Stock Is Still a Strong BuyWilliams-Sonoma: A Fundamentally Good Buy On Sale NowBy Thomas Hughes | May 23, 2025View Williams-Sonoma: A Fundamentally Good Buy On Sale NowKPTI, ACRS, ENTA, and MOLN Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.42 +0.02 (+1.43%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.46 +0.04 (+2.82%) As of 06/18/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Enanta Pharmaceuticals NASDAQ:ENTA$7.23 +0.18 (+2.55%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$7.27 +0.04 (+0.61%) As of 06/18/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Karyopharm Therapeutics NASDAQ:KPTI$4.44 +0.08 (+1.83%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$4.37 -0.07 (-1.67%) As of 06/18/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Molecular Partners NASDAQ:MOLN$3.75 -0.01 (-0.27%) Closing price 06/18/2025 03:39 PM EasternExtended Trading$3.82 +0.07 (+1.87%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
